Lilly Wins FDA Approval for Lung Cancer Drug
Posted on: Tuesday, 30 September 2008, 09:45 CDT
Eli Lilly and Company has received approval from the FDA for the use of Alimta in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer, for patients with nonsquamous histology.
This marks the third US indication for Alimta. In 2004, Alimta has received consecutive approvals: first in combination with cisplatin as a treatment for patients with malignant pleural mesothelioma, whose disease is unresectable or who are otherwise not candidates for curative surgery, and then as a single agent for the second-line treatment of patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy treatment.
The Alimta approval in first-line advanced NSCLC for nonsquamous cell histology is based on a Phase III, open-label randomized study (1725 patients) that evaluated Alimta plus cisplatin versus Gemzar plus cisplatin. Based on the same data, the FDA also approved a change to the second-line indication.
Alimta is indicated as a single agent for the treatment of patients with locally-advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy. Alimta is not indicated for treatment of patients with squamous cell non-small cell lung cancer.
Source: Datamonitor
Related Articles
- AlphaVax Announces Full Enrollment in Phase I/II Study of Active Immunotherapy in Patients with Advanced or Metastatic Cancer
- Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
- RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- Infinity and MedImmune Initiate Phase 1b Trial of IPI-504 in Combination With Taxotere in Patients With Advanced Solid Tumor Cancers; Combination With Taxotere Provides Additional Paths for Development of Novel Hsp90 Inhibitor in Lung, Prostate and Breas
- New Cancer Drug Satraplatin Predicted To Reach the Market in Mid 2007 for Second-Line Treatment of Patients With Hormone-Refractory Prostate Cancer
- Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
- FDA Approves Taxotere(R) for the Treatment of Patients With Advanced Stomach Cancer
- MultiVu Video Feed: FDA Approves New Treatment For Patients With Advanced Stomach Cancer
- OSI Pharmaceuticals Announces That Tarceva-R- Receives Positive Opinion in EU for the Treatment of Patients With Advanced Lung Cancer
- A Phase I Trial Combining High-Dose ^Sup 90^Y-Labeled Humanized Anti- CEA Monoclonal Antibody With Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
User Comments (0)
RSS Feeds